Trial Profile
A Single Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 8150 (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 17 May 2016 Time frame of Primary endpoint Number of Participants with Adverse Events (AEs) and Number of Participants who Discontinue due to AEs changed from Approximately 20 weeks to approximately 42 days. And also Time frame of Time-weighted Average Across 24 hours and Mean Time Weighted Average over 12 hours changed to Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose.
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.